GLASGOW, SCOTLAND, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc has been advised of a
significant increase in the share price and trading volume of the Company's shares beginning Monday February 25, 2019.
The Company has been advised by OTC Markets Group that the Company is the subject of a promotional campaign by newsletter
writers. The material being distributed contains promotional language pertaining to the Company's business, activities and future
share price. The promotional campaign coincides with, and appears to have affected, a significant increase in the share price and
trading volume of the Company's shares beginning Monday February 25, 2019.
The Company and its officers and directors did not authorize or participate in the promotional campaign in any way and do not
endorse it. The Company and its officers and directors only became aware of the promotional campaign when advised by OTC Markets
Group.
The Company and its officers and directors:
· Has never had contacted with nor knows who the promotional
writers are;
· Does not know if any of the promotional writers own shares of
the Company;
· Did not participate in, or benefit from, trading in the shares
of the Company during the promotional campaign;
· The information pertaining to the Company’s relationship with
Smart Home projects is not accurate;
· The promotional material contains information available to the
Public from the SEC site or the OTC Markets site;
· Some of the statements of the promotional material being the
opinion of the writers are overly promotional;
· The Company does not have any IR services, public relation
services, paid promotion, marketing or other related services at this time; and,
· The company does not have any convertible instruments at a
discount to the market at this time.
The Company and its officers and directors are unaware of any business reason for this market activity and price
increase. All material developments concerning the Company of which its officers and directors are aware have been disclosed
in the Company's filings with OTC Markets. The Company encourages anyone interested in the Company to review its filings with
OTC Markets (US).
About Rafina Innovations Inc.
Rafina Innovations Inc. operates two fully owned subsidiaries: 1. HCi Viocare Technologies: developing hardware
solutions aiming to empower the user by providing on demand information and enhancing living quality. The R&D center located in
Glasgow, Scotland, is working on a large portfolio of cutting edge, revolutionary and disruptive technologies in the fields of
Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports & Wellbeing, and DVT. The Company has developed a
unique sensing technology with the brand name Flexisense™, which uses a multitude of micro sensors to detect pressure as well as
shear that is unique over other sensing technologies. The sensors are wirelessly connected to smart devices providing real time and
on demand information. HCi Viocare Technologies works on a licensing business model. 2. HCi Viocare Clinics: creating the first
cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe.
Please visit:
www.rafinainnovations.com
http://flexisense.hciviocare.com/
www.hci-viocare.co.uk
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and
assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could",
and other similar words. All statements addressing product performance, events, or developments that the Company expects or
anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas
of athletic shoes and the information and performance of the Company's technology in such applications. Because the statements are
forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the
Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should
one or more of these risks or uncertainties materialize or should any of the Company's underlying assumptions prove correct, actual
results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's
forward-looking statements. In particular, the Company has acquired its first operational Prosthetics & Orthotics (P&O) clinic
and is continuing development efforts for its other biomedical technologies, including a "smart insole" and its Flexisense TM
sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing
expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as
required by law, Rafina Innovations Inc. disclaims any obligation to update or publicly announce any revisions to any of the
forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange,
securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this
release. Investors are advised to carefully review the reports and documents that Rafina Innovations files from time to time with
the SEC, including its Annual, Quarterly and Current Reports.
For Investors Relations: Constantinos Zertalis, CEO e: czertalis@rafinainnovations.com
